Allovir ROA 2024

Mitä Allovir tekee?

Allovir Inc was founded in 2013 in Cambridge, Massachusetts and is a biopharmaceutical company specializing in the development and commercialization of cellular immunotherapies for viral infections. The idea behind the founding of Allovir was to develop a new generation of immunotherapies with the potential to treat virus-related diseases that were previously difficult to treat. Allovir's business model is based on the development and commercialization of cellular immunotherapies that rely on the patient's immune system to fight infections. The company focuses on two main areas: infectious diseases and cancer. Within these areas, Allovir focuses on the development of therapies for severe viral infections such as BK virus, cytomegalovirus (CMV), and adenovirus, as well as the development of therapies to combat cancer. Allovir's first product candidates are Viral Associated Diseases (VAD) cell therapies developed to treat infections caused by BK virus, CMV, and adenovirus. These therapies consist of virus-specific T cells that are extracted from the patient's blood, amplified and activated in the laboratory, and then reintroduced into the patient where they can directly attack and eliminate the virus. Another promising product that Allovir is currently developing is ALVR106, a cellular immunotherapy for the treatment of cancer. ALVR106 is a CAR-T cell therapy candidate that aims to target HER2-positive solid tumors. The active ingredient is based on certain T cells that have been modified to specifically recognize and attack tumor-specific antigens. Allovir has conducted several successful clinical trials in recent years and has achieved promising results. Significant progress was observed in a clinical trial for the treatment of BK virus infections in kidney transplant patients. Therapy with virus-specific T cells resulted in a significant reduction in viral load and improvement in kidney function. Allovir's therapy also showed promising results in a Phase 2 trial for the treatment of CMV in bone marrow transplant patients. Allovir has established a strong position in the field of cellular immunotherapies for viral infections in recent years. The company has built an impressive research and development platform and has an experienced team of researchers and developers. The clinical results of Allovir's products demonstrate a high potential for future developments, and the company is expected to continue to grow and innovate in the coming years. Allovir ist eines der beliebtesten Unternehmen auf Eulerpool.com.